Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

Robin E. Buckingham(New Frontier), John C. Clapham(New Frontier), C. D. N. Toseland(New Frontier), Nicholas C. Turner(Institute of Cancer Research), Brian Bond(New Frontier), Susan C. Connor(New Frontier), Andrew West(New Frontier), Kamal Albarazanji(Springhouse), Mark S. Slaughter(University of Louisville)

Diabetes

August 1, 1998

10.2337/diab.47.8.1326

Cited by 205

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

|Annals of Oncology|2021|1.4k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

|Journal of Clinical Oncology|2018|925